Navigation Links
The Economist honors cancer immunotherapy pioneer James Allison
Date:11/7/2013

HOUSTON For basic science research that opened a completely new approach for treating cancer, The Economist has named James Allison, Ph.D., professor and chair of Immunology at The University of Texas MD Anderson Cancer Center, as its 2013 Innovations Award winner in Bioscience.

Allison identified an immune checkpoint molecule that turns off T cells white blood cells that are the attack dogs of the immune system before they can mount a successful response to tumors that they are primed to destroy.

An antibody that blocks that immune checkpoint molecule, unleashing a T cell attack, became the first drug to ever extend survival for patients with late-stage melanoma. The U.S. Food and Drug Administration approved ipilumumab (Yervoy) for treatment of metastatic melanoma in 2011.

"The approval of ipilimumab in 2011 represents the culmination of years of research by Dr Allison into tumor immunotherapy," said Tom Standage, Digital Editor at The Economist and chairman of the panel of 30 judges. "We are delighted to recognize his pioneering achievement in the fight against cancer."

The Economist is a 170-year-old weekly news publication based in London with a circulation of 4.5 million worldwide. Its Innovation Awards recognize significant contributions in eight fields: Bioscience, Computing and Telecommunications, Consumer Products, Energy and Environment, Process and Services, Social and Economic, No Boundaries and Corporate.

"I'm honored to receive this award, which recognizes the increasing importance of immune therapy in the treatment of cancer due to the efforts of many scientists, clinicians and patients willing to participate in clinical trials," Allison said.

The adaptive immune system routinely identifies, destroys and remembers infections and abnormal cells. Yet cancer cells evade or suppress immune attack, largely frustrating efforts to develop vaccines and other immune therapies against tumors.

Drug treats immune system, not specific tumor

"Immune checkpoint blockade treats the immune system, not the tumor, so we expect this approach to work across many types of cancer," Allison said. In addition to melanoma, ipilumumab has been effective in clinical trials against prostate, kidney, lung and ovarian cancers.

Allison's basic science research on T cell biology uncovered the receptor on these cells used to recognize and bind to antigens abnormalities that mark defective cells or viruses and bacteria for attack.

He also found that T cells require a second molecular signal to launch a response after they've bound to an antigen. And he identified a molecule called CTLA-4 that acts as an off switch to inhibit activated T cells from attacking.

This led to development of ipilumumab to block CTLA-4. In clinical trials against stage 4 melanoma, the drug extinguished the disease in 20 percent of patients for up to 12 years and counting.

Since arriving at MD Anderson in November 2012, Allison founded and directs an immunotherapy platform to cultivate, support and test new development of immunology-based drugs and combinations. MD Anderson's Moon Shots program, designed to accelerate the conversion of scientific discoveries into clinical advances that reduce cancer deaths, taps the expertise of the immunotherapy platform.

Allison earned his doctorate from The University of Texas at Austin in 1978, joining MD Anderson's faculty after his postdoctoral fellowship. He left MD Anderson for the University of California, Berkeley and later moved to Memorial Sloan-Kettering Cancer Center in New York.

He is a member of the National Academy of Sciences, the Institute of Medicine of the National Academies and has won many honors for biomedical research, including the first AACR-CRI Lloyd J. Old Award in Cancer Immunology at the annual meeting of the American Association for Cancer Research in April 2013.

Allison will receive his award at a ceremony in London on Dec. 3.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. National survey of economists uncovers vast gender gap in policy views
2. EmploymentCrossing Site Mirrors Economists Speculation of Job Growth
3. Amyotrophic Lateral Sclerosis Association honors Dr. Robert Baloh, M.D.
4. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
5. ASH honors Margaret A. Goodell, Ph.D., with 2012 William Dameshek Prize
6. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
7. Argentina honors Dr. Laurie H. Glimcher for enriching scientific cooperation
8. Speech-language researcher awarded top honors
9. Kentucky receives top honors in nations capital for health IT collaboration
10. Radiation Research Society honors 2 faculty
11. Bridges to Recovery Reaches Ten-Year Milestone as Premiere, Licensed Residential Behavioral Treatment Program and Honors Founding Medical Director Dr. Terry V. Eagan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and athletics. It’s enough to overwork even the sharpest brain. , Power On, ... peak healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, ...
(Date:2/22/2017)... ... ... The National Academy of Certified Care Managers (NACCM) has ... period. NACCM, a nonprofit organization, has provided the premier certification for Care Managers ... to ensure that newly certified professionals are prepared to work effectively on behalf ...
(Date:2/22/2017)... ... February 22, 2017 , ... A ... smaller and sometimes harder to reach ones, according to the results of a ... Stroke Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with ...
(Date:2/22/2017)... ... 2017 , ... The first-ever National Heart Valve Disease Awareness ... join together to increase recognition about the risks of heart valve disease (HVD) ... mark a nationwide movement to raise awareness about a disease that has not ...
(Date:2/22/2017)... Pittsburgh, PA (PRWEB) , ... February 22, 2017 , ... ... why some people seem to derive a heart-protective benefit from eating soy foods, while ... , Japanese men who are able to produce equol—a substance made by some ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... YORK , Feb. 22, 2017 Summary ... cell lung cancer partnering deals and agreements entered into ... full report: http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global ... 2010 report provides understanding and access to partnering deals ... companies. - Trends in partnering deals ...
(Date:2/22/2017)... Feb. 22, 2017  Corin Group announced today the ... used to treat patients with both a massive rotator ... The condition, known as cuff tear arthropathy, causes pain ... The Humelock Reversed Shoulder System, which was ... company based near Lyon, France , ...
(Date:2/22/2017)... 2017 Research and Markets has announced ... Review, 2016" report to their offering. ... Dermatological conditions are ... approximately one-third of the US population suffers from at least ... of the dermatology market has remained saturated with established and ...
Breaking Medicine Technology: